先声药业盘中涨超7% 先诺欣成国内首款常规批准新冠口服药

iDoNews
19 May

5月19日,先声药业股价盘中上涨超7%,现报9.28港元。其研发的先诺欣®是国内首款获得常规批准的口服抗新冠病毒药物,由先声药业与中科院上海药物研究所等联合开发,针对3CL靶点,拥有自主知识产权。该药物于2023年1月附条件获批上市,并纳入医保报销目录。近期,香港及内地新冠活跃程度较高,儿童和成人严重病例有所增加,推动市场关注相关药物。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10